Fermenta Biotech Ltd - Stock Valuation and Financial Performance

BSE: 506414 | NSE: | Pharmaceuticals & Drugs | Small Cap

Fermenta Biotech Share Price

152.55 5.55 3.78%
as on 28-Mar'24 16:01

DeciZen - make an informed investing decision on Fermenta Biotech

Overall Rating
M-Cap below 500cr. High Risk from low Liquidity Bole Toh

1. Quality

2. Valuation

Fair

3. Price Trend

Fermenta Biotech stock performance -

mw4me loader
P/E Ratio (SA):
0.00
Market Cap:
445.6 Cr.
52-wk low:
103.3
52-wk high:
214

Is Fermenta Biotech Ltd an attractive stock to invest in?

1. Is Fermenta Biotech Ltd a good quality company?

Past 10 year’s financial track record analysis by Moneyworks4me indicates that Fermenta Biotech Ltd is a below average quality company.

2. Is Fermenta Biotech Ltd undervalued or overvalued?

The key valuation ratios of Fermenta Biotech Ltd's currently when compared to its past seem to suggest it is in the Fair zone.

3. Is Fermenta Biotech Ltd a good buy now?

The Price Trend analysis by MoneyWorks4Me indicates it is Weak which suggest that the price of Fermenta Biotech Ltd is likely to Fall in the short term. However, please check the rating on Quality and Valuation before investing.

10 Year X-Ray of Fermenta Biotech:

Analysis of Financial Track Record

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.

Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
Fermenta Biotech Ltd has not performed well majority of the past ten years indicating its past ten year financial track record is not good

Value Creation

Value Creation Index Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
ROCE % 1.3%0.6%-5.8%-10.1%-7.3%39.2%15.6%11.4%6.5%-0.3%-
Value Creation
Index
-0.9-1.0-1.4-1.7-1.51.80.1-0.2-0.5-1.0-

Growth Parameters

Growth Parameters Colour Code Guide

Sales 15.213.56.15.512.5405301373388329318
Sales YoY Gr.--11%-54.6%-10.1%126.6%3,134.8%-25.7%24.1%4.1%-15.2%-
Adj EPS 0.50.3-3.3-6.6-7.24221.817.79.6-5.8-4.5
YoY Gr.--47.1%-1318.5%NANANA-48.1%-18.8%-46.1%-160.9%-
BVPS (₹) 33.833.63032.623.586.7106.3124.3132.2111.2109.2
Adj Net
Profit
1.40.7-9.1-18.3-19.911662.951.127.6-16.8-13
Cash Flow from Ops. 1.9-0.4-5-9.11.390.529.86350.4124-
Debt/CF from Ops. 13.7-93.3-11-4.9107.92.37.43.64.71.7-

CAGR

CAGR Colour Code Guide

9 Years 5 Years 3 Years 1 Years
Sales 40.7%92.3%3.1%-15.2%
Adj EPS -231.1%NA-164.4%-160.9%
BVPS14.1%36.4%1.5%-15.9%
Share Price 13.6% -11.1% -15.7% 36.1%

Key Financial Parameters

Performance Ratio Colour Code Guide

Mar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23TTM
Return on
Equity %
1.50.8-10.3-21.2-25.873.622.4157.2-4.6-4.1
Op. Profit
Mgn %
28.321.5-98.9-154-26.535.52325.719.812.216.9
Net Profit
Mgn %
9.35.5-147.6-331.3-159.228.620.913.77.1-5.1-4.2
Debt to
Equity
0.30.40.70.52.20.90.70.60.60.7-
Working Cap
Days
4244398661,020520111304308355383157
Cash Conv.
Cycle
-8-15-24-16-203512914116817116

Recent Performance Summary

Debt to equity has declined versus last 3 years average to 0.68

Return on Equity is Poor

Sales growth has been subdued in last 3 years 3.06%

Sales growth is not so good in last 4 quarters at 5.09%

Latest Financials - Fermenta Biotech Ltd.

Standalone Consolidated
TTM EPS (₹) -4.5 -6.8
TTM Sales (₹ Cr.) 318 343
BVPS (₹.) 109.2 100.9
Reserves (₹ Cr.) 307 282
P/BV 1.39 1.50
PE 0.00 0.00
From the Market
52 Week Low / High (₹) 103.30 / 214.00
All Time Low / High (₹) 4.90 / 442.00
Market Cap (₹ Cr.) 446
Equity (₹ Cr.) 14.7
Face Value (₹) 5
Industry PE 48.2

Management X-Ray of Fermenta Biotech:

Shareholding Pattern

Promoter's Holding & Share Pledging

Pledged *0.000.000.000.000.000.000.000.000.000.00
* Pledged shares as % of Promoter's holding (%)

Event Update

Login/Register to view analysis.

Analyst's Notes

Key Ratios of Fermenta Biotech

Adj EPS (Rs.)

Sales (Cr.)

ROE (%)

ROCE (%)

Profit And Loss

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Sales15146613405301373388329
Operating Expenses 1111131424277232278311290
Manufacturing Costs222464134445550
Material Costs000009283124144126
Employee Cost 455665350575954
Other Costs 5465129065535360
Operating Profit 43-7-9-1112869957739
Operating Profit Margin (%) 28.2%21.4%-108.0%-154.0%-90.1%31.6%22.8%25.4%19.8%12.0%
Other Income 001122614788
Interest 0026112120191821
Depreciation 222341215192425
Exceptional Items 000000000-60
Profit Before Tax 21-9-18-23121486343-59
Tax 1000111-161112-1
Profit After Tax 11-9-18-24110645230-58
PAT Margin (%) 9.4%5.4%-148.0%-331.0%-193.0%27.3%21.2%13.9%7.8%-17.5%
Adjusted EPS (₹)0.50.3-3.3-6.7-8.840.122.118.010.5-19.9
Dividend Payout Ratio (%)161%157%-6%-3%-2%1%23%14%12%-6%

Balance Sheet

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23

Equity and Liabilities

Shareholders Fund 9392839065249307358381321
Share Capital 22222514141414
Reserves 9190808762244292344367306
Minority Interest0000000000
Debt1501738138195206207212185
Long Term Debt150143413213510211011584
Short Term Debt00246601049697101
Trade Payables111124347464653
Others Liabilities 22504917184412108123109
Total Liabilities 131143149146223532572719762668

Fixed Assets

Gross Block2122100913128163315293322
Accumulated Depreciation13156122437657392
Net Fixed Assets8794812104126250220230
CWIP 34631102271573545
Investments 3940411161087672131316
Inventories0000088114133130110
Trade Receivables0000066779611867
Cash Equivalents 35163129132413155
Others Assets141712191008779130216145
Total Assets 131143149146223532572719762668

Cash Flow

(All Figures are in Crores.)
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Cash Flow From Operating Activity 20-5-9191306350124
PBT 21-9-18-23121486343-59
Adjustment 224102039344039148
Changes in Working Capital -1-21-25-36-38-27-2231
Tax Paid -1-2-11-1-33-14-13-95
Cash Flow From Investing Activity -20-11-820-89-97-39-44-32-64
Capex -20-28-21-8-4-35-64-55-37-40
Net Investments 001326-84-532424-16
Others 01702-1-9191-8
Cash Flow From Financing Activity 21914-138812-48-1-22-41
Net Proceeds from Shares 0000000000
Net Proceeds from Borrowing 251014006-34143-18
Interest Paid 00-2-6-9-20-21-18-17-21
Dividend Paid -3-1-1-1-1-1-60-7-4
Others -102-69828132-11
Net Cash Flow 2-21-216-5718-419
PARTICULARSMar'14Mar'15Mar'16Mar'17Mar'18Mar'19Mar'20Mar'21Mar'22Mar'23
Ratios
ROE (%)1.520.79-10.44-21.25-31.372.7823.3615.638.18-16.39
ROCE (%)1.930.87-5.46-8.47-7.5243.4613.8314.549.85-6.29
Asset Turnover Ratio0.130.10.040.040.071.070.540.580.520.46
PAT to CFO Conversion(x)20N/AN/AN/A0.830.471.211.67N/A
Working Capital Days
Receivable Days11761410308785101103
Inventory Days111200079122121123133
Payable Days0000090200137116142

Fermenta Biotech Ltd Stock News

Fermenta Biotech Ltd FAQs

Company share prices are keep on changing according to the market conditions. The closing price of Fermenta Biotech on 28-Mar-2024 16:01 is ₹152.6.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 28-Mar-2024 16:01 the market cap of Fermenta Biotech stood at ₹445.6.
The latest P/E ratio of Fermenta Biotech as of 28-Mar-2024 16:01 is 0.00.
The latest P/B ratio of Fermenta Biotech as of 28-Mar-2024 16:01 is 1.39.
The 52-week high of Fermenta Biotech is ₹214.0 and the 52-week low is ₹103.3.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Fermenta Biotech is ₹318.0 ( Cr.) .

About Fermenta Biotech Ltd

DIL Ltd. formerly Duphar-Interfran Limited is an Indian public listed company located at Thane, India. Founded in 1951 by Late Dr. D V K Raju in the name of International Franchises Private Limited. DIL has built successful partnerships with leading multinational companies for over 53 years. The name of the company was then changed to ‘Crookes Interfran Limited’ and then in 1971 the name was changed to ‘Duphar Interfran Ltd.’. In the year 1976, the company’s equity shares were listed on the Stock Exchange of Bombay (BSE). In 2000, the company demerged its pharmaceutical business into a new company called Duphar Pharma India Ltd. (currently known as Solvay Pharma India Ltd.) which issued to the shareholders of Duphar Interfran Ltd., 2 equity shares of Duphar Pharma India Ltd. for every 1 share held in Duphar Interfran Ltd. by the shareholders at that time, while retaining their original share in Duphar Interfran Ltd. The name of the company was then changed to DIL Limited.

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

With the growing global need for newer drugs and for research, DIL, with its capabilities, becomes a preferred partner for undertaking contract research and custom synthesis.

Specializing in synthesis of fine organic compounds, chiral building blocks and Intermediates, their expertise include developing small size, aromatic & non-aromatic, functionalized heterocycles, enzyme mediated asymmetric synthesis of hydroxyesters, protection of amino acids at amino and carboxyl functionalities and synthesis of compounds having peptide linkage.

From its fully-equipped and modern facilities, the multi-cultural team at DIL strives to offer the best services in organic synthesis and industrial biotechnology.  Qualified synthetic chemists develop and produce tailor-made compounds (Gms to multi-kegs) for the pharmaceutical and biotechnology industries. Their services cover both individual projects, as well as working exclusively as permanent team members for clients.

Offering expertise on both short and long-term projects, DIL seamlessly blends in as an extension of the client company, offering flexible and integrated services, made to measure solutions, cost-effective and on-time service accelerating drug discovery and development – backed by the assurance of confidentiality.

With all this, DIL enhances and adds value to the client’s research program. DIL is a public listed company delivering reliable services to the pharmaceutical and biotechnology industries. Tucked away in a quiet and verdant niche in Thane, (32 km. away from Mumbai), and spread over 28,000 sq mts of land, is where it all happens.

Business area of the company:

Currently, DIL is engaged in the business of research support services through its subsidiary Research Support International Ltd. (RSIL), manufacture and marketing of enzymes and chemicals through its subsidiary Fermenta Biotech Ltd. (FBL), entertainment through its subsidiary White Stripes Entertainment Ltd. (WSEL) and manufacture and marketing of levitation technology and wheel chairs through its Joint Venture company, being set up in the Czech Republic.

Milestones:

  • 1951 – 1963: Toll manufacturing for the pharmaceutical and cosmetics industries.
  • 1963: The company established a JV with Philips Duphar for the manufacture and marketing of pharmaceutical products in India.
  • 1976: DIL was listed on the Bombay Stock Exchange.
  • 1980: Philips Duphar was taken over by Solvay Pharmaceuticals.
  • 1986: Fermenta Biotech Ltd. was founded as a subsidiary company to complement and segregate DIL’s capabilities in biotechnology.
  • 1987: Fundamental research was initiated as part of Solvay’s research efforts. A full-fledged laboratory was set up as per GLP requirements and accredited by the Department of Scientific & Industrial Research.
  • 1995: ‘Crocin’, which went on to become the most popular brand of paracetamol in India, was divested to SmithKline Beecham.
  • 2000: The company realigned its business to focus sharply and exclusively on custom synthesis and process R&D by de-merging its pharmaceutical formulation business in favour of Solvay.

 

Read More Read Less
You have 2 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.